Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007:600:118-31.
doi: 10.1007/978-0-387-70956-7_10.

Semaphorin signaling in vascular and tumor biology

Affiliations
Review

Semaphorin signaling in vascular and tumor biology

Gera Neufeld et al. Adv Exp Med Biol. 2007.

Abstract

The neuropilins were originally characterized as cell membrane receptors that bind axon guidance factors belonging to the class-3 semaphorin subfamily. To transduce semaphorin signals, they form complexes with members of the plexin receptor family in which neuropilins serve as the ligand binding components and the plexins as the signal transducing components. The neuropilins were subsequently found to double as receptors for specific heparin binding splice forms of vascular endothelial growth factor (VEGF), and to be expressed on endothelial cells. This finding suggested that semaphorins may function as modulators of angiogenesis. It was recently found that several types of semaphorins such as semaphorin-3F function as inhibitors of angiogenesis while others, most notably semaphorin-4D, function as angiogenic factors. Furthermore, semaphorins such as semaphorin-3F and semaphorin-3B have been characterized as tumor suppressors and have been found to exert direct effects upon tumor cells. In this chapter we cover recent developments in this rapidly developing field of research.

PubMed Disclaimer

Similar articles

  • The semaphorins and their receptors as modulators of tumor progression.
    Neufeld G, Mumblat Y, Smolkin T, Toledano S, Nir-Zvi I, Ziv K, Kessler O. Neufeld G, et al. Drug Resist Updat. 2016 Nov;29:1-12. doi: 10.1016/j.drup.2016.08.001. Epub 2016 Aug 28. Drug Resist Updat. 2016. PMID: 27912840 Review.
  • Semaphorins in cancer.
    Neufeld G, Shraga-Heled N, Lange T, Guttmann-Raviv N, Herzog Y, Kessler O. Neufeld G, et al. Front Biosci. 2005 Jan 1;10:751-60. doi: 10.2741/1569. Print 2005 Jan 1. Front Biosci. 2005. PMID: 15569615 Review.
  • Semaphorin-3F is an inhibitor of tumor angiogenesis.
    Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, Machluf M, Neufeld G. Kessler O, et al. Cancer Res. 2004 Feb 1;64(3):1008-15. doi: 10.1158/0008-5472.can-03-3090. Cancer Res. 2004. PMID: 14871832
  • Semaphorins in angiogenesis and tumor progression.
    Neufeld G, Sabag AD, Rabinovicz N, Kessler O. Neufeld G, et al. Cold Spring Harb Perspect Med. 2012 Jan;2(1):a006718. doi: 10.1101/cshperspect.a006718. Cold Spring Harb Perspect Med. 2012. PMID: 22315716 Free PMC article. Review.
  • Class 3 semaphorin signaling: the end of a dogma.
    Potiron V, Roche J. Potiron V, et al. Sci STKE. 2005 May 24;2005(285):pe24. doi: 10.1126/stke.2852005pe24. Sci STKE. 2005. PMID: 15914725 Review.

Cited by

Publication types

MeSH terms

LinkOut - more resources